Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Biopharmaceutical company Hoth Therapeutics announced that its innovative therapy HT-001 has received approval from Spanish regulatory authorities to conduct a Phase 2a clinical trial.

Biopharmaceutical company Hoth Therapeutics announced that its innovative therapy HT-001 has received approval from Spanish regulatory authorities to conduct a Phase 2a clinical trial.

老虎证券老虎证券2026/05/05 20:23
Show original
This European authorization marks an important milestone in the development of the drug. The latest interim data disclosed shows that HT-001 demonstrates encouraging therapeutic effects in cancer patients. Preliminary trial results have confirmed the potential of this therapy in controlling tumor progression and improving patients’ clinical symptoms. Receiving recognition from the Spanish drug regulatory authorities provides a solid foundation for Hoth Therapeutics to further advance clinical research in the European market. The company plans to optimize subsequent trial protocols based on existing data and accelerate the global development of HT-001.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Masayoshi Son's Trillion-Dollar Gamble: Once Considered Acquiring SK Hynix

According to reports, Masayoshi Son once planned to acquire the South Korean memory chip giant SK Hynix for nearly 1 trillion US dollars and had approached Wall Street institutions to seek financing, but SoftBank has confirmed it is no longer actively pursuing the deal. The massive financing requirement and South Korean regulatory restrictions were major obstacles. This plan also highlights SoftBank’s further strategic intention to invest in AI storage chips.

华尔街见闻•2026/11/21 03:16

"Sell-offs bring more sell-offs! Goldman Sachs predicts another large-scale sell-off in the U.S. stock market in the coming week."

Goldman Sachs stated that the bank’s “panic index” has risen to 9 out of 10, with systemic selling pressure continuing to spread. In the coming week, CTAs may sell up to $80.6 billion in US stocks, and even if the market remains flat, there is still $65.8 billion in sell orders waiting to be executed. The Anthropic IPO failed to boost market risk appetite, and concerns over AI investment returns continue to weigh on tech stock valuations.

华尔街见闻•2026/11/21 02:16